BIOATLA, LLC
Conditionally Active Biologics (CAB) — engineered antibodies that activate only in the tumor microenvironment to kill cancer cells while sparing healthy tissue
- Sector
- Biotech
- Headquarters
- SAN DIEGO, CA
- Latest Form D
- $39M, Jul 2015
- Total capital
- $42.3M
- Federal grants
- $220K
- 1 award · 2016
- Rank in peer group#341 of 392
- Private capital raised
- $42.1M
- 2 Form D · last Jul 2015
- 135 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 20
- 20 pending · first 2023
- Rank in peer group#2 of 392
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Selective inhibition of platelet GPIb-alpha binding to leukocyte Mac-1 as a novel anti-thrombotic therapeutic$220K
- Private capital raisedForm D · SEC · 2nd filing$39M
- Private capital raisedForm D · SEC · 1st filing$3.1M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#2 · top 1%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Jay M. ShortResearcherExecutive Officer, DirectorLinked by 2 patents
- Carolyn M. ShortDirectorNamed in SEC Form D filings
- Richard A. WaldronExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 20 granted of 40- GrantedChimeric Antigen Receptors To HER2 And Methods Of Use ThereofUSPTOUS 12,742,020
- PendingANTI-CTLA4 Antibodies, Antibody Fragments, Their Immunoconjugates and Uses ThereofUSPTOApplication 19666809
- PendingMulti-specific Antibody ConstructsUSPTOApplication 19358938
Show all 40 patent records
- Chimeric Antigen Receptors To HER2 And Methods Of Use ThereofSep 22, 2026 · US 12,742,020Granted
- ANTI-CTLA4 Antibodies, Antibody Fragments, Their Immunoconjugates and Uses ThereofAug 27, 2026 · Application 19666809Pending
- Multi-specific Antibody ConstructsJun 18, 2026 · Application 19358938Pending
- ANTI-CTLA4 Antibodies, Antibody Fragments, Their Immunoconjugates and Uses ThereofJun 9, 2026 · US 12,649,793Granted
- Proteins Targeting OrthologsMay 19, 2026 · US 12,631,650Granted
- Comprehensive Monoclonal Antibody GenerationApr 7, 2026 · US 12,595,592Granted
- Conditionally Active Anti-epcam Antibodies, Antibody Fragments, Their Immunoconjugates And Uses ThereofFeb 26, 2026 · Application 19317515Pending
- Multi-specific Antibody ConstructsNov 18, 2025 · US 12,473,360Granted
- Conditionally Active Anti-epcam Antibodies, Antibody Fragments, Their Immunoconjugates And Uses ThereofSep 30, 2025 · US 12,427,347Granted
- Methods Of Treating Axl-expressing Cancers With Anti-axl Antibodies, Antibody Fragments And Their ImmunoconjugatesSep 4, 2025 · Application 18252542Pending
- ANTI-ROR2 Antibodies, Antibody Fragments, Their Immunoconjugates And Uses ThereofMay 29, 2025 · Application 19029723Pending
- ANTI-ROR2 Antibodies, Antibody Fragments, Their Immunoconjugates And Uses ThereofMay 27, 2025 · US 12,311,032Granted
- Cancer Treatment With A Conditionally Active ANTI-ROR2 Antibody-drug ConjugateMay 22, 2025 · Application 18841038Pending
- Chimeric Antigen Receptors Against Axl Or ROR2 And Methods Of Use ThereofJan 23, 2025 · Application 18907457Pending
- Chimeric Antigen Receptors Against Axl Or ROR2 And Methods Of Use ThereofJan 7, 2025 · US 12,187,801Granted
- Conditionally Active Biological ProteinsDec 19, 2024 · Application 18820633Pending
- Conditionally Active Proteins For Neurodegenerative DiseasesDec 5, 2024 · Application 18694273Pending
- Conditionally Active Biological ProteinsOct 8, 2024 · US 12,110,611Granted
- Simultaneous, Integrated Selection And Evolution Of Antibody/protein Performance And Expression In Production HostsAug 8, 2024 · Application 18612054Pending
- Anti-axl Antibodies, Antibody Fragments And Their Immunoconjugates And Uses ThereofJun 20, 2024 · Application 18402642Pending
- Simultaneous, Integrated Selection And Evolution Of Antibody/protein Performance And Expression In Production HostsMay 7, 2024 · US 11,976,381Granted
- Anti-Il-22 Antibodies, Antibody Fragments,Their Immunoconjugates And Uses ThereofMay 2, 2024 · Application 18491898Pending
- Anti-axl Antibodies, Antibody Fragments And Their Immunoconjugates And Uses ThereofFeb 13, 2024 · US 11,897,959Granted
- Protein Therapeutics For Treatment Of Senescent CellsFeb 8, 2024 · Application 18313341Pending
- ANTI-ROR2 Antibodies, Antibody Fragments, Their Immunoconjucates And Uses ThereofJan 23, 2024 · US 11,879,011Granted
- Humanized ANTI-CD73 AntibodiesJan 2, 2024 · US 11,859,007Granted
- Conditionally Active Anti-epcam Antibodies, Antibody Fragments, Their Immunoconjugates And Uses ThereofDec 26, 2023 · US 11,851,499Granted
- Anti-Il-22 Antibodies, Antibody Fragments,Their Immunoconjugates And Uses ThereofDec 5, 2023 · US 11,834,472Granted
- Method For Preparing A Conditionally Active Antibody Or Antibody FragmentNov 23, 2023 · Application 18341913Pending
- Mirac ProteinsOct 19, 2023 · Application 18334769Pending
- Conditionally Active Polypeptides And Methods Of Generating ThemOct 3, 2023 · US 11,773,509Granted
- Mirac ProteinsAug 8, 2023 · US 11,718,844Granted
- Conditionally Active ANTI-CD46 Antibodies, Antibody Fragments, Their Immunoconjugates And Uses ThereofAug 3, 2023 · Application 18002010Pending
- Conditionally Active ANTI-NECTIN-4 AntibodiesJul 27, 2023 · Application 18002064Pending
- Conditionally Active Chimeric Antigen Receptors For Modified T-cellsJun 15, 2023 · Application 18061197Pending
- Novel Methods Of Protein EvolutionMay 2, 2023 · US 11,639,365Granted
- Conditionally Active Anti-Her2 Antibodies, Antibody Fragments Their Immunoconjugates And Uses ThereofApr 6, 2023 · Application 17759195Pending
- Conditionally Active Chimeric Antigen Receptors For Modified T-cellsFeb 21, 2023 · US 11,584,927Granted
- ANTI-CTLA4 Antibodies, Antibody Fragments, Their Immunoconjugates and Uses ThereofJan 3, 2023 · US 11,542,332Granted
- Conditionally Active PolypeptidesDec 22, 2022 · Application 17820913Pending
Related companies, and why
- Oncoimmune IncSimilar federal contract value in Biotech · null in contracts
- GLOBIN SOLUTIONS INCSimilar federal contract value in Biotech · null in contracts
- ABACUS BIOSCIENCE INCSimilar federal contract value in Biotech · null in contracts
- TAMUROBIO INC.Similar federal contract value in Biotech · null in contracts
- MUSTANG BIO, INC.Similar federal contract value in Biotech · null in contracts
- UNDERDOG PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .